These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21389687)

  • 21. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.
    Probst G; Aubele DL; Bowers S; Dressen D; Garofalo AW; Hom RK; Konradi AW; Marugg JL; Mattson MN; Neitzel ML; Semko CM; Sham HL; Smith J; Sun M; Truong AP; Ye XM; Xu YZ; Dappen MS; Jagodzinski JJ; Keim PS; Peterson B; Latimer LH; Quincy D; Wu J; Goldbach E; Ness DK; Quinn KP; Sauer JM; Wong K; Zhang H; Zmolek W; Brigham EF; Kholodenko D; Hu K; Kwong GT; Lee M; Liao A; Motter RN; Sacayon P; Santiago P; Willits C; Bard F; Bova MP; Hemphill SS; Nguyen L; Ruslim L; Tanaka K; Tanaka P; Wallace W; Yednock TA; Basi GS
    J Med Chem; 2013 Jul; 56(13):5261-74. PubMed ID: 23713656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholestenoic acid, an endogenous cholesterol metabolite, is a potent γ-secretase modulator.
    Jung JI; Price AR; Ladd TB; Ran Y; Park HJ; Ceballos-Diaz C; Smithson LA; Hochhaus G; Tang Y; Akula R; Ba S; Koo EH; Shapiro G; Felsenstein KM; Golde TE
    Mol Neurodegener; 2015 Jul; 10():29. PubMed ID: 26169917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
    Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
    J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool.
    van Maanen EM; van Steeg TJ; Michener MS; Savage MJ; Kennedy ME; Kleijn HJ; Stone JA; Danhof M
    J Pharmacol Exp Ther; 2016 Apr; 357(1):205-16. PubMed ID: 26826190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers.
    Liu Q; Waltz S; Woodruff G; Ouyang J; Israel MA; Herrera C; Sarsoza F; Tanzi RE; Koo EH; Ringman JM; Goldstein LS; Wagner SL; Yuan SH
    JAMA Neurol; 2014 Dec; 71(12):1481-9. PubMed ID: 25285942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein.
    Yang T; Arslanova D; Gu Y; Augelli-Szafran C; Xia W
    Mol Brain; 2008 Nov; 1():15. PubMed ID: 18983676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease.
    Kounnas MZ; Danks AM; Cheng S; Tyree C; Ackerman E; Zhang X; Ahn K; Nguyen P; Comer D; Mao L; Yu C; Pleynet D; Digregorio PJ; Velicelebi G; Stauderman KA; Comer WT; Mobley WC; Li YM; Sisodia SS; Tanzi RE; Wagner SL
    Neuron; 2010 Sep; 67(5):769-80. PubMed ID: 20826309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic inhibition of Aβ production by combinations of γ-secretase modulators.
    Robertson AS; Iben LG; Wei C; Meredith JE; Drexler DM; Banks M; Vite GD; Olson RE; Thompson LA; Albright CF; Ahlijanian MK; Toyn JH
    Eur J Pharmacol; 2017 Oct; 812():104-112. PubMed ID: 28690193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.
    Rogers K; Felsenstein KM; Hrdlicka L; Tu Z; Albayya F; Lee W; Hopp S; Miller MJ; Spaulding D; Yang Z; Hodgdon H; Nolan S; Wen M; Costa D; Blain JF; Freeman E; De Strooper B; Vulsteke V; Scrocchi L; Zetterberg H; Portelius E; Hutter-Paier B; Havas D; Ahlijanian M; Flood D; Leventhal L; Shapiro G; Patzke H; Chesworth R; Koenig G
    Mol Neurodegener; 2012 Dec; 7():61. PubMed ID: 23249765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CTF1-51, a truncated carboxyl-terminal fragment of amyloid precursor protein, suppresses the effects of Aβ42-lowering γ-secretase modulators.
    Watahiki H; Yagishita S; Futai E; Ishiura S
    Neurosci Lett; 2012 Sep; 526(2):96-9. PubMed ID: 22940081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Method for the determination of the levels of beta-amyloid peptide in the CSF sampled from freely moving rats.
    El Mouedden M; Haseldonckx M; Mackie C; Meert T; Mercken M
    J Pharmacol Toxicol Methods; 2005; 52(2):229-33. PubMed ID: 16125620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects.
    Toyn JH; Boy KM; Raybon J; Meredith JE; Robertson AS; Guss V; Hoque N; Sweeney F; Zhuo X; Clarke W; Snow K; Denton RR; Zuev D; Thompson LA; Morrison J; Grace J; Berisha F; Furlong M; Wang JS; Lentz KA; Padmanabha R; Cook L; Wei C; Drexler DM; Macor JE; Albright CF; Gasior M; Olson RE; Hong Q; Soares HD; AbuTarif M; Ahlijanian MK
    J Pharmacol Exp Ther; 2016 Jul; 358(1):125-37. PubMed ID: 27189974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention.
    Rynearson KD; Ponnusamy M; Prikhodko O; Xie Y; Zhang C; Nguyen P; Hug B; Sawa M; Becker A; Spencer B; Florio J; Mante M; Salehi B; Arias C; Galasko D; Head BP; Johnson G; Lin JH; Duddy SK; Rissman RA; Mobley WC; Thinakaran G; Tanzi RE; Wagner SL
    J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33651103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats.
    Wu G; Wu Z; Na S; Hershey JC
    Int J Neurosci; 2015; 125(8):616-24. PubMed ID: 25567290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
    Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
    J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys.
    Fischer C; Zultanski SL; Zhou H; Methot JL; Shah S; Hayashi I; Hughes BL; Moxham CM; Bays NW; Smotrov N; Hill AD; Pan BS; Wu Z; Moy LY; Tanga F; Kenific C; Cruz JC; Walker D; Bouthillette M; Nikov GN; Deshmukh SV; Jeliazkova-Mecheva VV; Diaz D; Michener MS; Cook JJ; Munoz B; Shearman MS
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3488-94. PubMed ID: 26212776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.
    Gravenfors Y; Viklund J; Blid J; Ginman T; Karlström S; Kihlström J; Kolmodin K; Lindström J; von Berg S; von Kieseritzky F; Bogar K; Slivo C; Swahn BM; Olsson LL; Johansson P; Eketjäll S; Fälting J; Jeppsson F; Strömberg K; Janson J; Rahm F
    J Med Chem; 2012 Nov; 55(21):9297-311. PubMed ID: 23017051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.